Please login to the form below
Pronova
This page shows the latest Pronova news and features for those working in and with pharma, biotech and healthcare.
FDA approves AZ’s fish oil drug
Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product.
Latest news
-
Teva launches first generic of GSK's Lovaza in US
GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... An earlier settlement between ProNova and Apotex gave the generics company rights to
-
AZ target Omthera files blood fat drug in US
There is competition in the hypertriglyceridemia area, however, and if approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved
-
AstraZeneca offers $443m to buy Omthera
weeks. If approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved end-user sales of around $1.4bn in
-
Early 2013 sees drug filings, launches and approvals in Japan
originator Pronova BioPharma of Norway.
-
GSK acquires Reliant Pharmaceuticals
The drug, the US rights of which were in-licensed from Norway-based Pronova BioPharma, is indicated as an adjunct to diet. ... Pronova will continue to supply the product's primary material. Rights to Lovaza in other markets have been licensed by the
More from news
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2012
that corresponds to a 24 per cent premium on Pronova's average six month share price and values the company at about 5.7 times annual earnings. ... 900. Pronova BioPharma / BASF. Acquisition. Omega-3 fatty acids. Active ingredient for Lovaza, p
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
